Johnson & Johnson (NYSE:JNJ) Shares Bought by Natixis Advisors LLC

Natixis Advisors LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 19.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,556,013 shares of the company's stock after purchasing an additional 254,861 shares during the quarter. Natixis Advisors LLC owned approximately 0.06% of Johnson & Johnson worth $252,168,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Summit Wealth Partners LLC raised its holdings in Johnson & Johnson by 0.6% in the 2nd quarter. Summit Wealth Partners LLC now owns 10,007 shares of the company's stock valued at $1,463,000 after acquiring an additional 61 shares during the last quarter. Powers Advisory Group LLC boosted its stake in Johnson & Johnson by 0.6% in the 3rd quarter. Powers Advisory Group LLC now owns 9,489 shares of the company's stock worth $1,538,000 after buying an additional 61 shares during the last quarter. Citizens & Northern Corp increased its stake in shares of Johnson & Johnson by 3.5% during the 2nd quarter. Citizens & Northern Corp now owns 1,884 shares of the company's stock valued at $275,000 after acquiring an additional 63 shares during the last quarter. Eagle Wealth Strategies LLC lifted its holdings in shares of Johnson & Johnson by 2.8% during the 3rd quarter. Eagle Wealth Strategies LLC now owns 2,294 shares of the company's stock worth $372,000 after acquiring an additional 63 shares during the period. Finally, Epic Trust Investment Advisors LLC boosted its position in shares of Johnson & Johnson by 3.6% in the second quarter. Epic Trust Investment Advisors LLC now owns 1,831 shares of the company's stock worth $268,000 after acquiring an additional 64 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $154.00 on Friday. The business has a 50 day moving average price of $161.35 and a two-hundred day moving average price of $156.02. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The firm has a market cap of $370.77 billion, a PE ratio of 22.29, a price-to-earnings-growth ratio of 2.72 and a beta of 0.53. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to analyst estimates of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business's revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.66 earnings per share. Sell-side analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.22%. Johnson & Johnson's payout ratio is 71.78%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on JNJ shares. Citigroup lifted their price target on shares of Johnson & Johnson from $180.00 to $185.00 and gave the company a "buy" rating in a report on Wednesday, October 16th. Cantor Fitzgerald restated an "overweight" rating and set a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Guggenheim lifted their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a "neutral" rating in a research note on Wednesday, November 6th. Daiwa America downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, July 23rd. Finally, The Goldman Sachs Group decreased their price objective on shares of Johnson & Johnson from $160.00 to $155.00 and set a "neutral" rating for the company in a research note on Friday, July 19th. Seven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $175.94.

Insider Activity at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the business's stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares of the company's stock, valued at $3,131,683.38. This represents a 22.90 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.